Fabrizio Carta | Medicinal Chemistry | Pharmaceutical Research Excellence Award

Published on by Top Pharmaceutical

Prof. Fabrizio Carta | Medicinal Chemistry | Pharmaceutical Research Excellence Award

Universita’ degli Studi di di Firenze | Italy

Prof. Fabrizio Carta is an accomplished medicinal chemist and academic leader whose research bridges rational drug design, molecular pharmacology, and structure–activity relationship analysis to address critical unmet medical needs. As an Associate Professor of Medicinal Chemistry at the University of Florence, within the Department of Neuroscience, Psychology, Drug Area and Child Health (NEUROFARBA), he has established an internationally recognized research profile centered on the discovery and optimization of innovative bioactive compounds of both natural and synthetic origin. His scientific vision integrates chemical creativity with biological insight, enabling the development of next-generation therapeutic agents with improved selectivity, efficacy, and safety profiles.His research activity spans three interconnected domains. The first focuses on the rational design and synthesis of novel small molecules targeting challenging disease pathways, with particular emphasis on antiglaucoma, anti-obesity, anticancer, and antiviral agents. The second domain is dedicated to the in-depth molecular characterization of biological activity and mechanisms of action, combining chemical synthesis, biochemical evaluation, and pharmacological validation to uncover new drug targets and signaling pathways. The third domain involves advanced structure–activity relationship studies, often supported by structural biology data, to guide structure-based optimization and minimize off-target effects.A major hallmark of Prof. Carta’s work is his pioneering contribution to the field of carbonic anhydrase modulation. As principal investigator or co-investigator on multiple funded projects, he has designed and synthesized a broad spectrum of carbonic anhydrase inhibitors and modulators belonging to diverse chemical classes, including sulfonamides, sulfamides, sulfamates, carboxylic acids, coumarins, polyamines, phenols, dithiocarbamates, xanthates, and monothiocarbamates. Notably, he contributed to the discovery of entirely new inhibitor classes, significantly expanding the chemical space of zinc-binding motifs and influencing subsequent drug discovery efforts. His work also played a key role in the development of a clinically advanced carbonic anhydrase IX inhibitor for the management of hypoxic tumors.

Citation Metrics (Google Scholar)

15000

10000

5000

1000

0

Citations
14,790

h-index
66

i10-index
227

■ Citations
■ h-index
■ i10-index


View Google Scholar Profile

Featured Publications

Ali Darehkordi | Medicinal Chemistry | Research Excellence Award

Published on by Top Pharmaceutical

Prof. Dr. Ali Darehkordi | Medicinal Chemistry | Research Excellence Award

Vali-e-Asr University of Rafsanjan | Iran

Prof. Dr. Ali Darehkordi is a distinguished Iranian chemist whose academic and professional career reflects deep expertise in organic synthesis, catalysis, drug modification, heterocyclic chemistry, and the design of biologically active fluorinated compounds. He holds a Ph.D., M.Sc., and B.Sc. in Organic Chemistry and Chemistry from leading Iranian universities, with a strong foundational background in natural sciences. Beginning his academic journey as an instructor in the Faculty of Science at Vali-e-Asr University of Rafsanjan, he steadily advanced through key academic ranks, serving as Assistant Professor, Associate Professor, and ultimately Professor of Organic Chemistry. Throughout his career, he has also held several important administrative and leadership roles, including Deputy of the Faculty of Science, Director of the Department of Chemistry, and repeated appointments as Head of the Faculty of Basic Sciences, where he contributed to academic development, departmental management, curriculum enhancement, and research advancement.Prof. Darehkordi’s research accomplishments have earned him multiple awards, including several Excellent Researcher Awards at the faculty, departmental, and university levels, recognizing his contributions to both scientific research and industrial collaboration. His scientific interests span a wide range of advanced topics, such as the design, synthesis, and biological evaluation of trifluoromethylated heterocyclic compounds with anticancer potential, catalysis reactions, drug modification using trifluoroacetimidoyl chlorides, organic synthesis pathways, carbohydrate reaction mechanisms, and herbal medicine applications. His laboratory expertise includes hands-on proficiency with NMR, FT-IR, microwave reactors, ultrasound systems, and polarimetry, supporting his ability to conduct complex chemical characterizations and innovative synthesis techniques.As an active researcher with extensive contributions to international journals, Prof. Darehkordi has authored impactful publications, including A novel bistrifluoromethylated compound as highly efficient nematicide against root-knot nematode on pistachio and docking study, Antitumor activities of a novel fluorinated small molecule (A1) in CT26 colorectal cancer cells: molecular docking and in vitro studies, and A facile and catalyst-free microwave-promoted method for the synthesis of 3-trifluoromethyl 1,2,4-triazole-5-thiones. These publications highlight his innovative chemical synthesis approaches, application-driven research mindset, and strong integration of computational docking, biological testing, and modern reaction methodologies. Prof. Dr. Ali Darehkordi continues to stand as a leading scientist in organic and medicinal chemistry, contributing meaningfully to drug discovery, reaction design, and fluorinated molecule development.

Profile: Google Scholar

Featured Publications

Moghadam, M. R., Jahromi, S. M. P., & Darehkordi, A. (2016). Simultaneous spectrophotometric determination of copper, cobalt, nickel and iron in foodstuffs and vegetables with a new bis thiosemicarbazone ligand using chemometric approaches. Food Chemistry, 192, 424–431.

Darehkordi, A., Saidi, K., & Islami, M. R. (2007). Preparation of heterocyclic compounds by reaction of dimethyl and diethyl acetylene dicarboxylate (DMAD, DEAD) with thiosemicarbazone derivatives. Arkivoc, 1, 180–188.

Darehkordi, A., Rahmani, F., & Hashemi, V. (2013). Synthesis of new trifluoromethylated indole derivatives. Tetrahedron Letters, 54(35), 4689–4692.

Funt, L. D., Tomashenko, O. A., Novikov, M. S., & Khlebnikov, A. F. (2018). An azirine strategy for the synthesis of alkyl 4-amino-5-(trifluoromethyl)-1H-pyrrole-2-carboxylates. Synthesis, 50(24), 4809–4822.

Karimabad, M. N., Mahmoodi, M., Jafarzadeh, A., Darehkordi, A., Hajizadeh, M. R., et al. (2017). The novel Indole-3-formaldehyde (2-AITFEI-3-F) is involved in processes of apoptosis induction? Life Sciences, 181, 31–44.

Karimabad, M. N., Mahmoodi, M., Jafarzadeh, A., Darehkordi, A., Hajizadeh, M. R., et al. (2017). Evaluating of OCT-4 and NANOG was differentially regulated by a new derivative indole in leukemia cell line. Immunology Letters, 190, 7–14.

Galal Elgemeie | Medicinal Chemistry | Best Researcher Award

Published on by Top Pharmaceutical

Prof. Dr. Galal Elgemeie | Medicinal Chemistry | Best Researcher Award

Helwan University | Egypt

Prof. Elgemeie stands as a distinguished figure in the field of organic and medicinal chemistry, with a research career deeply rooted in the development and mechanistic understanding of organic reactions and their applications in synthesizing antimetabolic agents. His scholarly pursuits bridge fundamental chemistry with biomedical innovation, particularly in the discovery of novel therapeutic compounds aimed at combating cancer and viral diseases. Through his extensive academic contributions, he has established a legacy of excellence that continues to inspire scientists and researchers globally.An internationally recognized scientist, Prof. Elgemeie was elected as a member of the Scientific Board of the International Basic Sciences Programme (IBSP) under UNESCO in Paris, France, reflecting his global influence and leadership in advancing the chemical sciences. His postdoctoral experiences across Germany, the United States, and England—supported by prestigious foundations such as the Alexander von Humboldt Foundation, the Fulbright Program, and the British Council—shaped his multidisciplinary expertise and broadened his research collaborations across continents.Prof. Elgemeie’s innovative research has led to numerous impactful projects, including the design and synthesis of novel epigenetic small molecules and antimetabolites in collaboration with the Institute of Medicinal Chemistry, Düsseldorf University. His pioneering work in developing sofosbuvir analogues for treating hepatitis C virus (HCV) and hepatocellular carcinoma among Egyptian patients demonstrates his commitment to translating scientific discovery into therapeutic applications with real-world benefits.His publication record is exceptional, with over 270 papers indexed in international databases such as Scopus, and his scientific influence is further underscored by a significant citation index. He has authored influential scientific books with leading publishers like Elsevier, offering comprehensive insights into cancer metabolism and heterocyclic chemistry. Prof. Elgemeie also holds several patents in process, reflecting his drive to innovate beyond academia and contribute to industry-based advancements in medicinal chemistry.Serving as an editorial board member for prominent journals including Current Microwave Chemistry, he continues to guide the global scientific dialogue in his field. His collaborations span several institutions worldwide, reinforcing his reputation as a bridge between Egyptian and international research communities.Beyond research, Prof. Elgemeie has played a vital role in educational reform and academic development across Egypt and the Arab region. He has supervised multiple cooperative projects with the European Community under the TEMPUS programme, contributing to the restructuring of higher education and aligning it with international standards. These initiatives have significantly advanced institutional capacity and innovation within Mediterranean and Arab universities.

Profile: Orcid

Featured Publications

Azzam, R. A., Seif, M. M., El-Demellawy, M. A., & Elgemeie, G. H. (2025). Novel 2-substituted benzothiazole derivatives: Synthesis, in vitro and in silico evaluations as potential anticancer agents. RSC Advances.

Elgemeie, G. H., Fathy, N. M., & Shaarawi, S. I. (2024). Naphthyl cyanoketene N, S-acetals in glycoside synthesis: A new preparative route to a new class of N-naphthylcyanoacrylamide thioglycosides and their conversions to naphthyl–pyrazole hybrids. Nucleosides, Nucleotides & Nucleic Acids.

Abu-Zaied, M. A., Nawwar, G. A., & Elgemeie, G. H. (2024). Novel synthesis of a new class of substituted S-glycosylisothiourea derivatives and their conversion to 5-amino-1,2,4-triazoles. Synthetic Communications.

Metwally, N. H., Elgemeie, G. H., & Fahmy, F. G. (2023). Synthesis and biological evaluation of benzothiazolyl-pyridine hybrids as new antiviral agents against H5N1 bird flu and SARS-CoV-2 viruses. ACS Omega.

Abdallah, A. E. M., Abdel-Latif, S. A., & Elgemeie, G. H. (2023). Novel fluorescent benzothiazolyl-coumarin hybrids as anti-SARS-COVID-2 agents supported by molecular docking studies: Design, synthesis, X-ray crystal structures, DFT, and TD-DFT/PCM calculations. ACS Omega.

Ahmed, E. A., Elgemeie, G. H., & Azzam, R. A. (2023). Synthesis of new sulfapyrimidine and pyrazolo[1,5-a]pyrimidine derivatives. Synthetic Communications.

Khedr, M. A., Zaghary, W. A., Elsherif, G. E., Azzam, R. A., & Elgemeie, G. H. (2023). Purine analogs: Synthesis, evaluation and molecular dynamics of pyrazolopyrimidines-based benzothiazole as anticancer and antimicrobial CDK inhibitors. Nucleosides, Nucleotides & Nucleic Acids.

Karanvir Singh | Medicinal Chemistry | Best Researcher Award

Published on by Top Pharmaceutical

Mr. Karanvir Singh | Medicinal Chemistry | India

Guru Nanak Dev University | India

Mr. Karanvir Singh is a dynamic and highly skilled researcher in the field of pharmaceutical chemistry, currently pursuing his Doctorate of Philosophy at the Department of Pharmaceutical Sciences, Guru Nanak Dev University, Amritsar, India. His ongoing doctoral research, under the supervision of Prof. Dr. Preet Mohinder Singh Bedi, focuses on the design and synthesis of 1,2,4-triazine hybrids with Nipecotic acid for anticonvulsant activity, emphasizing computational modeling, synthesis, and biological evaluation of novel anticonvulsant agents. He holds a Master’s degree in Pharmacy (Pharmaceutical Chemistry) from ISF College of Pharmacy, Moga, Punjab, where he completed a thesis on the design and synthesis of 1,2,4-triazine derivatives for anticonvulsant activity under the guidance of Dr. Vikramdeep Monga and Dr. Bhupinder Kumar. His strong academic foundation was built upon a Bachelor of Pharmacy from the Laureate Institute of Pharmacy, Himachal Pradesh.With a blend of academic excellence and industrial exposure, Mr. Singh has worked as an Assistant QA Chemist at United Biotech Pvt. Ltd., where he gained extensive experience in pharmaceutical quality assurance. His scientific expertise spans molecular docking, fragment-based drug design, pharmacophore modeling, molecular dynamics simulations, organic synthesis, compound purification, and structural elucidation using analytical tools such as NMR, FT-IR, HPLC, and Mass spectrometry.Mr. Singh has made significant contributions to the scientific community, authoring multiple research and review articles in reputed journals. His notable publications include Design, Synthesis, and Biological Evaluation of Triazole-Linked Lignan–Monoterpenoid-Based Hybrid Molecules as Xanthine Oxidase Inhibitors with Potent In Vivo Efficacy; Design, Synthesis, and Multi-Target Biological Evaluation of 1,2,3-Triazole Linked Indole–Thiazolidinedione Hybrids as Potent α-Glucosidase, α-Amylase, and DPP-4 Inhibitors with Antioxidant Potential; Design, Synthesis, Antibacterial Evaluation, and Molecular Modelling Studies of 1,2,3-Triazole-Linked Coumarin–Vanillin Hybrids as Potential DNA Gyrase and Topoisomerase IV Inhibitors; and Development of Coumarin-Inspired Bifunctional Hybrids as a New Class of Anti-Alzheimer’s Agents with Potent In Vivo Efficacy. His review works, such as Exploring Norfloxacin Analogs in Combating Antimicrobial Resistance: Design, Mechanistic Insights, and Structure–Activity Relationship and Incredible Indolinedione Derivatives Nucleus in the Development of Anti-Diabetic Drugs: Exploring the Mechanistic Studies, Design, and Structure–Activity Relationship, further demonstrate his broad research vision and scientific depth.

Profile: Google Scholar

Featured Publications

Singh, K., Pal, R., Khan, S. A., Kumar, B., & Akhtar, M. J. Insights into the structure–activity relationship of nitrogen-containing heterocyclics for the development of antidepressant compounds: An updated review. Journal of Molecular Structure.

Singh, A., Malhotra, D., Singh, K., Chadha, R., & Bedi, P. M. S. Thiazole derivatives in medicinal chemistry: Recent advancements in synthetic strategies, structure–activity relationship, and pharmacological outcomes. Journal of Molecular Structure.

Singh, A., Singh, K., Sharma, A., Kaur, K., Kaur, K., Chadha, R., & Bedi, P. M. S. Recent developments in synthetic α-glucosidase inhibitors: A comprehensive review with structural and molecular insight. Journal of Molecular Structure.

Pal, R., Singh, K., Khan, S. A., Chawla, P., Kumar, B., & Akhtar, M. J. Reactive metabolites of the anticonvulsant drugs and approaches to minimize the adverse drug reaction. European Journal of Medicinal Chemistry.

Singh, A., Singh, K., Sharma, A., Kaur, K., Chadha, R., & Bedi, P. M. S. Recent advances in antifungal drug development targeting lanosterol 14α-demethylase (CYP51): A comprehensive review with structural and molecular insights. Chemical Biology & Drug Design.